《2025年美国肝病学会实践指导： 肝细胞癌的预防、诊断和治疗（关键更新）》解读

赵宇泽; 陈宇枭; 王科淳; 王明达; 杨田

doi:10.12449/JCH250509

《2025年美国肝病学会实践指导：肝细胞癌的预防、诊断和治疗（关键更新）》解读

DOI: 10.12449/JCH250509

赵宇泽^{1, 2},
陈宇枭^{1, 2},
王科淳¹,
王明达¹,
杨田^1, , ,

1.
海军军医大学东方肝胆外科医院肝外二科，上海 200438
2.
海军军医大学基础医学院，上海 200438

基金项目:

国家自然科学基金 (82425049);

国家自然科学基金 (82273074);

国家自然科学基金 (81972726);

上海市优秀学术带头人计划项目 (23XD1424900);

上海市卫生健康学科带头人项目 (2022XD001);

上海市自然科学基金 (22ZR1477900)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：赵宇泽、陈宇枭、王科淳负责文章翻译；王明达、杨田负责文章审校。赵宇泽与陈宇枭对本文贡献等同。

详细信息

通信作者:
杨田， yangtian6666@hotmail.com （ORCID： 0000-0003-1544-0976）

计量
- 文章访问数: 994
- HTML全文浏览量: 35
- PDF下载量: 92
- 被引次数: 0
出版历程
- 收稿日期: 2025-04-08
- 录用日期: 2025-04-22
- 出版日期: 2025-05-25

Interpretation of critical update： AASLD practice guidance on prevention， diagnosis， and treatment of hepatocellular carcinoma

Yuze ZHAO^{1, 2},
Yuxiao CHEN^{1, 2},
Kechun WANG¹,
Mingda WANG¹,
Tian YANG^{1
, ,
,}

1.
Second Department of Hepatic Surgery，Eastern Hepatobiliary Surgery Hospital，Naval Medical University，Shanghai 200438，China
2.
College of Basic Medicine，Naval Medical University，Shanghai 200438，China

Research funding:

National Natural Science Foundation of China (82425049);

National Natural Science Foundation of China (82273074);

National Natural Science Foundation of China (81972726);

Shanghai Outstanding Academic Leader Program (23XD1424900);

Shanghai Health Academic Leader Program (2022XD001);

Natural Science Foundation of Shanghai (22ZR1477900)

More Information

Corresponding author: YANG Tian， yangtian6666@hotmail.com （ORCID： 0000-0003-1544-0976）

摘要

摘要: 2025年2月，美国肝病学会（AASLD）在线发表了肝细胞癌的预防、诊断和治疗实践指导的关键更新。此次实践指导更新主要围绕IMbrave050研究最新发布的分析结果，结合临床实际问题进行了相应的建议更新与调整。针对以免疫检查点抑制剂为基础的肝细胞癌术后辅助治疗策略，AASLD重新考虑并对实践指导进行更新。实践指导更新调整了辅助治疗相关文本内容、指南建议以及进行辅助治疗期间或之后出现肝细胞癌复发患者的管理流程图。此外，AASLD强调，即使是切除/局部消融术后的高复发风险肝细胞癌患者，目前的标准治疗方案仍是密切监测复发情况。笔者团队对该实践指导更新进行摘译，系统介绍此次更新的相关背景及具体内容，并对肝细胞癌辅助治疗进行讨论，以供读者参考学习。
- 癌，肝细胞 /
- 预防 /
- 诊断 /
- 治疗学 /
- 美国 /
- 共识
Abstract: In February 2025， the American Association for the Study of Liver Diseases （AASLD） published online “Critical Update： AASLD Practice Guidance on Prevention， Diagnosis， and Treatment of Hepatocellular Carcinoma”. This update mainly focuses on the latest analysis results of the IMbrave050 study and performs corresponding updates and adjustments to recommendations based on the issues in clinical practice. As for the postoperative adjuvant therapeutic strategies for hepatocellular carcinoma （HCC） based on immune checkpoint inhibitors， the AASLD has re-evaluated and updated the practice guidance. The update revises related texts and recommendations for adjuvant therapy and the management algorithms for HCC recurrence during or after adjuvant therapy. Furthermore， the AASLD emphasizes that even for HCC patients at a high risk of recurrence after resection or local ablation， close monitoring for recurrence remains the current standard treatment regimen. Our team makes an excerpt of the update， systematically introduces the background and specific contents of the update， and discuss the adjuvant therapy for HCC， in order to provide a reference for readers.
- Carcinoma， Hepatocellular /
- Prevention /
- Diagnosis /
- Therapeutics /
- United States /
- Consensus

HTML全文

图 1 根治性的手术切除或局部消融治疗后HCC复发患者的管理流程

Figure 1. Management of patients with recurrence after complete response to resection or local ablation

下载: 全尺寸图片幻灯片

参考文献(4)

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
[2]	TADDEI TH, BROWN DB, YARCHOAN M, et al. Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2025. DOI: 10.1097/HEP.0000000000001269.[ Epub ahead of print]
[3]	QIN SK, CHEN MS, CHENG AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma(IMbrave050): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402( 10415): 1835- 1847. DOI: 10.1016/S0140-6736(23)01796-8.
[4]	YOPP A, KUDO M, CHEN M, et al. LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab(atezo)+bevacizumab(bev) vs active surveillance in patients(pts) with resected or ablated high-risk hepatocellular carcinoma(HCC)[J]. Ann Oncol, 2024, 35: S1230. DOI: 10.1016/j.annonc.2024.08.2279.